Individualized ATG dosing for stem cell transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a personalized dosing strategy for anti-thymocyte globulin (ATG) in adult patients undergoing unrelated donor allogeneic hematopoietic stem cell transplantation. The study aims to optimize ATG exposure to minimize complications such as cytomegalovirus reactivation and graft-versus-host disease. By monitoring ATG concentrations and adjusting doses accordingly, the trial seeks to improve patient outcomes and reduce the risks associated with standard dosing. The primary endpoint is the incidence of CMV reactivation at 180 days post-transplant.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation.
2. HLA-matched unrelated donor
3. Patient age ≥14 years old and ≤65 years old
4. ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values
5. Creatinine ≤ high limit of normal value
6. No uncontrollable infection or serious mental illness
7. Physical strength score is 0-2 (ECOG)
8. Sign the informed consent form

Exclusion Criteria:

1. Unrelated donor who is not HLA matched
2. No indication for allogeneic hematopoietic stem cell transplantation
3. Patient age \<14 years old or \>65 years old
4. The donor or recipient are pregnant
5. Suffering from mental illness or other conditions and being unable to proceed as planned

Where it's running

• Department of Hematology, First Medical Center of Chinese PLA General Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: diahong Liu, MD — The First Medical Center of Chinese PLA General Hospital
• Study coordinator: Sheng Chen, master
• Email: csto301@163.com
• Phone: 15101156205

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Combining ruxolitinib with corticosteroids for severe acute graft‑versus‑host disease

  This trial tests whether adding ruxolitinib to corticosteroids as first‑line treatment helps people who develop severe acute graft‑versus‑host disease after a first stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07509749

• Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant

  This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07358195

• First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease

  This trial will test whether adding ruxolitinib to standard corticosteroids helps people with new grade II acute graft-versus-host disease after an allogeneic stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07340723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.